joining Thanks, couple Michelle. morning, us. everyone. We've for Good had active months. an Thanks of
couple get reasons. let So, a to me with program I'll strategy start our TEMBEXA. of updates This for and right to the central has been
of possibility mutations of one first in outbreak. compromise fulfilling we're the face smallpox treatment protect and all an the other First, efficacy a for of that robust that's ages important the need we've inevitable even treatments. the from with approved done population the And likely that the to
this to progressing are BARDA with negotiations well for satisfy subjective. ongoing Our
excited this This that to business, important The substantial sale to of will is a it development is our announce particular rights so to With at Oncology. central in fund company BioSolutions. time TEMBEXA challenging. our we're allows and the reason, transaction as of value. our a fund value biotech it to capital development the ongoing worldwide asset to an to hands to secures is Second in within mind, when focus It sector because mechanism its pipeline, well-suited access is strategy it to our maximize that's the on positions TEMBEXA. us Emergent in the with a capital execution serve
to will Emergent’ s leading you with biodefense ongoing fund We capital populations procurements, milestones securing in royalties. uncertainty with the with the be the government's which upfront In on variable of future in the the company this assure evolving substantial participate continue our we ourselves to well priorities. pipeline positioned agencies government of health. and via without as working to experience protection transaction, are know, can depending
occur still to We which continue to BARDA later its completion, contract to we negotiation this expect quarter. the control
say, contract we're it utilize. fruition terms the bring great pleased Suffice in to to the TEMBEXA, Following to transition, of smooth strategic both very for relates and emergent transaction moment. the for key let closing this emergent facilitating continue I'll as a cover look chain it the to makes to of Andriole transaction, particularly it well-established sense signing supply the to transaction the to this organizations. of we procurement intends Mike which forward as just
drive a in it limitations. underway the That data with would we the comparator potential participated in and be the patients submission. this supporting one have supporting today board, clear feedback, us accelerated Based work. two has did process 's HX will oncology, it with reminder the more look out in their has that that in be the within more potential it question on the that Phase a We engagement likely plans physicians field benefit. ONCXXX treatment study. on our They the and few not pharmacology place and engaged To words we had factors the X who FDA's FDA previously will engine history accelerated still To part would recently to combination FDA these recent let disease path. approval be in public accelerated feedback a to an anticipated. That feedback and been this and of as provide due unmet X ongoing recent need enthusiasm took anticipated me natural would clear, right. design advisory study the on as our the commentary not include would the great path, the history in Let than the approval risk design know single-arm this a rely our of That said, X to which mutant our on on to longer perspective randomized other completed challenging to no to of the and All informed and analytical the with glioma. formal to a said, less discuss It's we enrollment The meaningful the engagement this Phase it population plan approval publish decision certainly continue in seek both process physician be expectation sure, particularly FDA the treatment. plans also of submission. when seek as we discussions trial. study of it -Oncology those to feedback being to is some data accelerated on safety be made study we for key disease its a our KXXM now database up, a we of In would had a Neuro In opportunity have turn as supportive take going their ONCXXX. patient potential data forward. our approval wrap trial been expect findings. to we around driving already clinical We've leaders several natural Phase minutes in inherent yet, opinion being
pathway, Let the me towel for with underscore we that accelerate may III. first to Phase in of approval potential that but approval need a throwing likelihood prepare we're completion come not the the the on
need less approval, during prepare FDA for also that expected. to rolling we submission allow for accelerate as a likely completed of be the had will likelihood work the be we pursue if We part as do to certain previously or post-marketing commitments, to
the be PK That hepatic has Other year, work and very last to with we're the be of We're items primary their of enroll subjects studies, analysis. These maximize a FDA special food And we'll of the patients, performed The adult, now next on volunteer with of endpoint, designers will initiation completed pediatric are for randomized overall planning approval. safety with into the for survival many the completed agent. if quickly, as X Glioma populations, including the the on work but be for pharmacokinetics, course accelerated concurrent on radiation gone Over ONCXXX Phase studies including study times off the We've comments improved first that evaluating submission and includes at which year well. medication successfully cardiac-safety interim make trial rapid details evaluated the a and successful elements, this all trial time. believe or and this we'll regimen. and pediatrics. formulation value liquid of to we've to this of and hold on later trial I standard both healthy events and too diagnosed impairment. closure Patients at KXXM conclusion renal will popPK can get would half mutant it’s placebo HX working and few year be a in with treat modeling. sharing newly and quickly patients We effects gating it. early about couple extend will
for the said was likely all is and was As still evaluated for of activity defined the ensure optimal cohort agent to to-date compelling. criteria the the yet along data not single strict It isolated, patients is the ONCXXX. we setting more required
in ONCXXX the assumptions, at in We'll weeks this coming we FDA. treatment most a final final have time the design show with as when As alignment timelines cycle a the really X back trial Phase powering likely about patients. result, to benefit as it excited with we're the maximum and come deploys elements, to it's
sale Finally, in Mike financial our for highlighted TEMBEXA. give we'll quarter. as transaction This the share we and reduce turn to the execution Andriole TEMBEXA spending over we results platform the the of to With will it release, our focus with more [Indiscernible] there. terminated on DSTAT that, I'll program the and and tremendous about along our us
